Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation

NCT06138587 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia
Leukemia
Leukemia, Myeloid
Myelodysplastic Syndromes
Myeloproliferative Neoplasm
Myeloproliferative Disorders

Interventions

BIOLOGICAL: Cytokine Induced Memory-like Natural Killer Cells
BIOLOGICAL: Interleukin-2

Sponsor

Dana-Farber Cancer Institute